An HHS spokesperson tells Reuters that the FDA is “actively re-evaluating” whether to proceed with the Advisory Committee meeting that had been planned to discuss Capricor Therapeutics (CAPR)’ Biologics License Application for Deramiocel, the company’s lead cell therapy candidate for the treatment of Duchenne Muscular Dystrophy-associated cardiomyopathy. Capricor provided regulatory updates earlier today related to its BLA for Deramiocel and stated that as part of the FDA’s ongoing review, the company has been informed that an Advisory Committee meeting is not indicated at this time.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics provides regulatory update on Deramiocel BLA
- Roth says ‘excessive’ Capricor selloff due to ‘investor overreaction’
- Capricor selloff brings buying opportunity, says H.C. Wainwright
- Capricor Therapeutics price target lowered to $22 from $43 at Oppenheimer
- Capricor Therapeutics participates in a conference call with Cantor Fitzgerald